Retraction to: Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population (Current Medical Research and Opinion, (2011), 27, 6, (1141-1148), 10.1185/03007995.2011.570747);Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: A meta-analysis of randomized controlled trials among the Japanese population

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1141-1148

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Matsumoto, Hideo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ALS; Bisphosphonate; Hip fracture; Immobilization; Parkinson's disease; Stroke

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; PLACEBO; RISEDRONIC ACID;

ABDOMINAL PAIN; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DATA ANALYSIS; DIARRHEA; DISABLED PERSON; DRUG EFFICACY; ESOPHAGITIS; HIP FRACTURE; HUMAN; JAPANESE; LEUKOPENIA; MEDLINE; META ANALYSIS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; STROKE;

EID: 79956089564     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1299998     Document Type: Erratum

References (36)

1. Sato Y, Honda Y, Iwamoto J. Etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized controlled trial. Bone 2006;39:1080-6 (Pubitemid 44528370)
2. Sato Y, Iwamoto J, Honda Y. Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke. J Stroke Cerebrovasc Dis 2010;19:198-203
3. Sato Y, Iwamoto J, Honda Y. An open-label trial comparing alendronate and alphacalcidol in reducing falls and hip fractures in disabled stroke patients. J Stroke Cerebrovasc Dis 2011;20:41-6
4. 2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924-9 (Pubitemid 44184591)
5. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165:1743-8 (Pubitemid 41138962)
6. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;64:811-16 (Pubitemid 40316317)
7. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007; 68:911-15 (Pubitemid 46568502)
8. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8 (Pubitemid 34925651)
9. Iwamoto J, Takeda T, Sato Y. Prevention and treatment of corticosteroid-induced osteoporosis. Yonsei Med J 2005;46:456-63 (Pubitemid 41283054)
10. Iwamoto J, Takeda T, Sato Y. Effects of antifracture drugs in postmenopausal male and glucocorticoid-induced osteoporosis-Usefulness of alendronate and risedronate. Expert Opin Pharmacother 2007;8:2743-56 (Pubitemid 350193714)
11. Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 2006;22: 919-28 (Pubitemid 43875559)
12. Iwamoto J, Matsumoto H, Takeda T. Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008;24:1379-84 (Pubitemid 351741570)
13. MoherD, CookDJ, Eastwoods, et al. Improving the quality of reports of metaanalyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-900
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60
15. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4. Chichester, England: John Wiley & Sons Ltd, 2005
16. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Clin Epidemiol 2005;58:882-93 (Pubitemid 41115772)
17. FujitaT, OrimoH, InoueT, et al. Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol. J Bone Miner Metab 2007;25:130-7 (Pubitemid 46328669)
18. Shiraki M, Kushida K, Fukunaga M, et al. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J 1998;45:191-201 (Pubitemid 28259398)
19. Uchida S, Taniguchi T, Shimizu T, et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 2005;23:382-8 (Pubitemid 41223801)
20. Ogura Y, Gonsho A, Cyong JC, et al. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 2004;22:111-19 (Pubitemid 38405039)
21. 3. Bone Miner 1987;3:47-52 (Pubitemid 18039736)
22. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370-6 (Pubitemid 24138753)
23. Orimo H, Yaegashi Y, OnodaT, et al. Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos 2009;4:71-7
24. Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanism of action of bisphosphonates. Bone 1999;24(5 Suppl.):73S-9S
25. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 2005;80:379-88 (Pubitemid 40316301)
26. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;23:CD001155
27. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;23:CD004523
28. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16:468-74
29. Liberman UA, Hochberg MC, Geusens P, et al. Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. Int J Clin Pract 2006;60:1394-400 (Pubitemid 44560336)
30. Epstein S. Is cortical bone hip? What determines cortical bone properties? Bone 2007;41 (Suppl 1):S3-8 (Pubitemid 46921511)
31. Iwamoto J, Sato Y, Takeda T, et al. Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 2008;3:483-9
32. Sato Y, Inose M, Higuchi I, et al. Changes in the supporting muscles of the fractured hip in elderly women. Bone 2002;30:325-30 (Pubitemid 34048326)
33. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006 (Pubitemid 38544282)
34. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64 (Pubitemid 40629192)
35. 3 receptor in human skelet al muscle tissue. Histochem J 2001; 33:19-24 (Pubitemid 32368054)
36. Sato Y, Iwamoto J, Kanoko T, et al. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis 2005; 20:187-92 (Pubitemid 41254180)